Probabilities of overall survival and DFS.

(A) Probability of overall survival of BCR-ABL⁺patients versus BCR-ABL⁻ patients. Probability of overall survival at 3 years of 175 BCR-ABL⁺ patients (0.15 ± 0.03 SE) and 257 BCR-ABL⁻ patients (0.47 ± 0.03 SE) treated in the GMALL studies 04/89 and 05/93. Log-rank P = .0001. (B) Probability of DFS of BCR-ABL⁺ patients versus BCR-ABL⁻ patients including those undergoing BMT. Probability of DFS at 3 years for 120 BCR-ABL⁺ patients (0.13 ± 0.03 SE) and 217 BCR-ABL⁻ patients (0.47 ± 0.04 SE) treated in the GMALL studies 04/89 and 05/93. Log-rank P = .0001. (C) Probability of DFS survival of BCR-ABL⁺ patients versus BCR-ABL⁻ patients without including the patients undergoing BMT. Probability of DFS at 3 years for 62 BCR-ABL⁺ patients (0.06 ± 0.03 SE) and 200 BCR-ABL⁻ patients (0.49 ± 0.04 SE) treated in the GMALL studies 04/89 and 05/93. Log-rank P = .0001. Solid line (top line in each graph) indicates BCR-ABL⁺; broken line (bottom line in each graph), BCR-ABL⁻.